Stockscreener 앱 받기
1.38
1.43%
-0.02
시간 외 거래:
1.33
-0.05
-3.62%
전일 마감가:
$1.40
열려 있는:
$1.38
하루 거래량:
100.71K
Relative Volume:
0.11
시가총액:
$7.58M
수익:
$3.25M
순이익/손실:
$-8.34M
주가수익비율:
-0.5358
EPS:
-2.5755
순현금흐름:
$-7.71M
1주 성능:
+1.47%
1개월 성능:
-4.17%
6개월 성능:
+97.45%
1년 성능:
-36.70%
1일 변동 폭
$1.35
$1.40
1주일 범위
$1.35
$1.46
52주 변동 폭
$0.575
$2.4999
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
명칭
Inmed Pharmaceuticals Inc
전화
(604) 669-7207
주소
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, TEVA, HLN, ZTS, VTRS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
1.38 | 7.58M | 3.25M | -8.34M | -7.71M | -2.5755 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Inmed Pharmaceuticals Inc 주식(INM)의 최신 뉴스
InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET - TMX Newsfile
InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 - TMX Newsfile
InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules - TMX Newsfile
InMed Pharmaceuticals (INM) Faces Nasdaq Equity Shortfall Amid I - GuruFocus
Form 8K INMED PHARMACEUTICALS INC. For: 18 September By Investing.com - Investing.com Nigeria
InMed Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
InMed Faces Nasdaq Equity Shortfall but Banks on Mentari Merger to Regain Compliance - TipRanks
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance - TMX Newsfile
10% owner adds to InMed Pharmaceuticals (INM) stake with open-market buys - Stock Titan
InMed Reports FY2026 Net Loss Of $12.9 Million As Mentari Merger Advances With $490 Million Financing - Pulse 2.0
InMed winds down only revenue-generating business BayMedica - Minichart
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
InMed Pharmaceuticals Inc. FY 2026: Revenue $3.18M, EPS ($3.12) — 10-K Summary - TradingView
[S-4/A] InMed Pharmaceuticals Inc. Amended Business Combination Registration | INM SEC FilingForm S-4/A - Stock Titan
$490M backs proposed migraine merger at InMed Pharmaceuticals (INM)—what legacy holders keep - Stock Titan
About $490 million in financing is expected before a proposed merger. InMed still needs shareholder approval. - Stock Titan
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update - TMX Newsfile
InMed Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
InMed Pharmaceuticals Inc. (INM) Peer Comparison – Compare with Others - Value Research
InMed (INM) Earnings Update: The Company Publishes Its Latest Results in the Latest Session; Price Reaction: Shares Close 7.59% Lower for the Current SessionPre-Earnings Setup - dars.gov.et
InMed (INM) Price: Finishes 7.59% Down at $1.46 in the Latest Session; Technical Setup: Price Remains Between $1.39 Support and $1.53 Resistance under the Current SnapshotIntraday Profile - vinanet.vn
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateEarnings Growth Forecast - vinanet.vn
InMed (INM) Session: Adds 0.63% to Close at $1.60 in Latest Trading; Current Setup: Traders Can Monitor the $1.52-$1.68 RangeVolatility Skew - vinanet.vn
InMed Pharmaceuticals (INM) Holds Above Support After 2.8% GainCash Secured Put - vinanet.vn
INM Q3 2025 Earnings: Net Loss of $1.94 Per Share; Stock Rises 2.8%One-Time Gain Impact - vinanet.vn
InMed Pharmaceuticals (INM) investor reports 4.2% beneficial stake in 137,634 shares - Stock Titan
Inmed Pharmaceuticals Stock Price Forecast. Should You Buy INM? - StockInvest.us
INM Q3 2025 Earnings: Net Loss of $1.94 Per Share Reflects Ongoing Biopharmaceutical InvestmentRevenue Breakdown Analysis - vinanet.vn
INM Q3 2025 Earnings: Net Loss of $1.94 Per Share ReportedFinancial Data - Vinanet
InMed Pharmaceuticals (INM) Rises 3.55% to $1.46 as Buyers Defend Key SupportMA Crossover - dars.gov.et
InMed Pharmaceuticals Inc (INM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InMed Pharmaceuticals (INM) Slips 6% to $1.40 as Support Level Comes into FocusCalendar Spread Trade - careplusvn.com
InMed Pharmaceuticals (INM) Rises 2.40% as Shares Approach Key $1.58 ResistanceSMA Signal - careplusvn.com
INM Q3 2025 Earnings: Net Loss of $1.94 Per Share Reflects Ongoing Clinical InvestmentEarnings Per Share - careplusvn.com
INM Q3 2025 Earnings: Narrowing Losses and Cautious Pipeline ProgressRevenue Growth Report - vinanet.vn
InMed Pharmaceuticals Inc (INM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InMed Pharmaceuticals Inc (INM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InMed Pharmaceuticals Inc (INM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InMed Pharmaceuticals Inc (INM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InMed Pharmaceuticals Inc (INM) Institutional Confidence - TradingKey
INM|InMed Pharmaceuticals Inc|Price:1.580|Chg%:-0.130 - TradingKey
TradingKey - TradingKey
INM|InMed Pharmaceuticals Inc|Price:1.670|Chg%:-0.040 - TradingKey
InMed Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:INM - TradingView
InMed Pharmaceuticals Inc (INM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ADAR1 Capital Management, LLC Acquires Additional Shares in InMed Pharmaceuticals Inc - GuruFocus
INM Q3 2025 Earnings: InMed Pharmaceuticals Reports Net Loss of $1.94 Per Share as Stock Rises 11.45%Guidance Accuracy Score - dars.gov.et
Mentari Therapeutics Raises $200 Million for Migraine Prevention Pipeline Ahead of InMed Merger - Minichart
InMed Pharmaceuticals (INM) plans Mentari merger with $490M financings - Stock Titan
InMed to Merge with Mentari as Mentari Secures $200M Pre-Closing Financing - TradingView
InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - Benzinga
Inmed Pharmaceuticals Inc (INM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.69%
자본화:
|
볼륨(24시간):